ClinicalTrials.gg
CompletedNCT03268382Updated Mar 17, 2025Results posted

p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246

A Phase 2 interventional study of APR-246 and Pegylated Liposomal Doxorubicin Hydrochloride (PLD) in High-grade Serous Ovarian Cancer, sponsored by Aprea Therapeutics. Completed at 12 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-17.

Sponsored by Aprea Therapeutics · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

The purpose of this study is to make a preliminary assessment of the efficacy of a combined APR-246 and PLD chemotherapy regimen in patients with platinum-resistant recurrent high grade serous ovarian cancer (HGSOC) with mutated TP53. In addition, the study aims to assess the safety profile of the combined APR-246 and PLD chemotherapy regimen, to evaluate potential biomarkers, and to assess the biological activity in tumor and surrogate tissues. The trial will enroll at least 25 evaluable patients.

02

Conditions studied

  • High-grade Serous Ovarian Cancer

Keywords

  • Ovarian Cancer
  • Ovarian Carcinoma
  • High Grade Serous Ovarian Cancer
  • Recurrent Cancer
  • Resistant Cancer
03

In context

Ovarian Neoplasms

3,381 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

This study's enrollment of 36 is below the median of 54 across 2,548 interventional studies indexed under Ovarian Neoplasms.

Browse Ovarian Neoplasms studies →

Lead sponsor

Aprea Therapeutics is the lead sponsor of 12 studies on the registry; 1 is open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed High Grade Serous Ovarian Cancer, and positive nuclear immunohistochemical (IHC) staining for p53
  • Disease Progression between 4 weeks - 6 months after the last platinum-based treatment was administered
  • At least a single
  • Adequate organ function prior to registration
  • Toxicities from previous cancer therapies (excluding alopecia) must have recovered to grade 1 (defined by National Cancer Institute [NCI] [CTCAE] version 4.0). Chronic stable grade 2 peripheral neuropathy secondary to neurotoxicity from prior therapies may be considered on a case by case basis
  • performance status of 0 to 2

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to cumulative doses of doxorubicin >400 mg/m2 or epirubicin >720 mg/m2
  • to PLD or to any of the
  • Unable to undergo imaging by either CT scan or MRI
  • Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, neurological conditions, physical examination or laboratory findings) that may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment related complications
  • Concurrent requiring therapy (excluding non-invasive carcinoma or carcinoma in situ)
  • Is taking concurrent (or within 4 weeks prior to registration) chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy that is considered to be (i.e., used for non-approved indications(s) and in the context of a research investigation). Supportive care measures are allowed. Palliative limited radiation therapy for pain reduction is allowed
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    APR-246 + PLD

    Drug: APR-246 · Drug: Pegylated Liposomal Doxorubicin Hydrochloride (PLD)

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: Up to 18 months

Secondary outcomes

  1. Treatment-emergent Adverse Events With Combined APR-246 and PLD Regimen

    Treatment emergent adverse events (TEAEs) were defined as AEs that occurred on or after the first dose of study medication up to and including 30 days after last dose. AEs were graded according to NCI CTCAE (Version 4.0). Patients with multiple TEAEs were only counted once within a summary category: SOC, PT, maximum grade, or relationship to treatment. Patients with events in more than one category were counted once within each category.

    Time frame: Treatment emergent adverse events (TEAEs) were defined as AEs that occurred on or after the first dose of study medication up to and including 30 days after last dose. Median number of 28d Cycles=2.5 (Min = 1, Max = 14)

07

Results

Posted Jul 21, 2022

Participant flow

Participant flow — Overall Study
MilestoneAPR-246 (4.5g/6hr) + PLDAPR-246 (4.5g/3hr) +PLDAPR-246 (4.5g/4hr) +PLDAPR-246 (3.7g/4hr) +PLD
Started28323
Completed28323
Not completed0000

Outcome measures

PrimaryOverall Response Rate (ORR)

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
Up to 18 months
Reported as:
Count of participants · Participants
Overall Response Rate (ORR)
ParticipantsAPR-246 (4.5g/6hr) + PLDAPR-246 (4.5g/3hr) + PLDAPR-246 (4.5g/4hr) + PLDAPR-246 (3.7g/4hr) + PLD
Partial Response (PR)1000
Stable Disease (SD)15211
Progressive Disease (PD)7012
Not Evaluable0100
Disease Control Rate (CR+PR+SD)16000
SecondaryTreatment-emergent Adverse Events With Combined APR-246 and PLD Regimen

Treatment emergent adverse events (TEAEs) were defined as AEs that occurred on or after the first dose of study medication up to and including 30 days after last dose. AEs were graded according to NCI CTCAE (Version 4.0). Patients with multiple TEAEs were only counted once within a summary category: SOC, PT, maximum grade, or relationship to treatment. Patients with events in more than one category were counted once within each category.

Time frame:
Treatment emergent adverse events (TEAEs) were defined as AEs that occurred on or after the first dose of study medication up to and including 30 days after last dose. Median number of 28d Cycles=2.5 (Min = 1, Max = 14)
Reported as:
Count of participants · Participants
Treatment-emergent Adverse Events With Combined APR-246 and PLD Regimen
ParticipantsAPR-246 (4.5g/6hr) + PLDAPR-246 (4.5g/3hr) + PLDAPR-246 (4.5g/4hr) + PLDAPR-246 (3.7g/4hr) + PLD
With Any Treatment-Emergent Adverse Events (TEAEs)28323
With APR-246 Related TEAEs25323
With PLD Related TEAEs24323
With Severity Grade >=314323
With Severity Grade >=3 APR-246 Related TEAEs6222
With Severity Grade >=3 PLD Related TEAEs7202
With Any Serious AEs11112
With Any Serious, APR-246 Related AEs4111
With Any Serious, PLD Related AEs2101
Who Discontinued APR-246 Due to TEAEs2100
Who Discontinued PLD Due to TEAEs0000
Who Died Due to any TEAEs0000

Adverse events

Collected over Treatment emergent adverse events (TEAEs) were defined as AEs that occurred on or after the first dose of study medication up to and including 30 days after last dose. Median number of 28d Cycles=2.5 (Min = 1, Max = 14). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
APR-246 (4.5g/6hr) + PLD9/28 (32.1%)11/28 (39.3%)28/28 (100%)
APR-246 (4.5g/3hr) + PLD1/3 (33.3%)1/3 (33.3%)3/3 (100%)
APR-246 (4.5g/4hr) + PLD0/2 (0%)1/2 (50%)2/2 (100%)
APR-246 (3.7g/4hr) + PLD1/3 (33.3%)2/3 (66.7%)3/3 (100%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventAPR-246 (4.5g/6hr) + PLDAPR-246 (4.5g/3hr) + PLDAPR-246 (4.5g/4hr) + PLDAPR-246 (3.7g/4hr) + PLD
DizzinessNervous system disorders0/280/31/20/3
InfectionInfections and infestations0/281/30/21/3
Device related infectionInfections and infestations0/280/30/21/3
Respiratory tract infectionInfections and infestations0/280/30/21/3
Urinary tract infectionInfections and infestations0/281/30/20/3
ThrombocytopeniaBlood and lymphatic system disorders0/281/30/20/3
Intestinal obstructionGastrointestinal disorders3/280/30/20/3
NauseaGastrointestinal disorders1/280/30/20/3
Peritoneal fibrosisGastrointestinal disorders1/280/30/20/3
Small intestinal obstructionGastrointestinal disorders1/280/30/20/3
Most frequent other events
Showing 10 of 81
Most frequent other events
EventAPR-246 (4.5g/6hr) + PLDAPR-246 (4.5g/3hr) + PLDAPR-246 (4.5g/4hr) + PLDAPR-246 (3.7g/4hr) + PLD
NauseaGastrointestinal disorders17/282/31/23/3
VomitingGastrointestinal disorders12/282/32/23/3
Abdominal painGastrointestinal disorders9/280/31/23/3
FatigueGeneral disorders6/283/31/23/3
DizzinessNervous system disorders5/281/32/21/3
Decreased appetiteMetabolism and nutrition disorders7/281/31/23/3
ConstipationGastrointestinal disorders11/281/30/22/3
DiarrheaGastrointestinal disorders6/280/30/22/3
Gastroesophageal reflux diseaseGastrointestinal disorders0/280/30/22/3
Device occlusionGeneral disorders0/280/30/22/3

Baseline characteristics

Patients with Pt-resistant HGSOC with TP53 mutation.

Age, Categorical
Age, Categorical(Participants)APR-246 (4.5g/6hr) + PLDAPR-246 (4.5g/3hr) + PLDAPR-246 (4.5g/4hr) + PLDAPR-246 (3.7g/4hr) + PLDTotal
<=18 years00000
Between 18 and 65 years2121226
>=65 years711110
Sex: Female, Male
Sex: Female, Male(Participants)APR-246 (4.5g/6hr) + PLDAPR-246 (4.5g/3hr) + PLDAPR-246 (4.5g/4hr) + PLDAPR-246 (3.7g/4hr) + PLDTotal
Female2832336
Male00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)APR-246 (4.5g/6hr) + PLDAPR-246 (4.5g/3hr) + PLDAPR-246 (4.5g/4hr) + PLDAPR-246 (3.7g/4hr) + PLDTotal
White2732335
Asian10001
Region of Enrollment
Region of Enrollment(participants)APR-246 (4.5g/6hr) + PLDAPR-246 (4.5g/3hr) + PLDAPR-246 (4.5g/4hr) + PLDAPR-246 (3.7g/4hr) + PLDTotal
Belgium40004
United Kingdom332311
Spain2100021
08

Study locations

12 sites
  • Medische oncologie, Universitair Ziekenhuis Gent
    Gent, 9000, Belgium
  • Leuven University Hospitals
    Leuven, B-3000, Belgium
  • Centre Hospitalier Universitaire de Liège
    Liège, B-4000, Belgium
  • Institut Català d'Oncologia, Hospital Germans Trias i Pujol
    Badalona, 08916, Spain
  • Hospital Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Universitario Fundación Jiménez Díaz
    Madrid, 28040, Spain
  • Hospital Universitario HM Sanchinarro
    Madrid, 28050, Spain
  • Hospital Clinico Universitario de Valencia
    Valencia, 46010, Spain
  • Cambridge Cancer Trials Centre, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital
    Cambridge, CB2 0QQ, United Kingdom
  • Edinburgh Cancer Research Centre, The University of Edinburgh
    Edinburgh, EH4 2XR, United Kingdom
  • The Royal Marsden NHS Foundation Trust
    London, SM2 5PT, United Kingdom
  • Imperial College London, Hammersmith Hospital Campus
    London, W12 0NN, United Kingdom
09

References and documents

Publications

  • Lehmann S, Bykov VJ, Ali D, Andren O, Cherif H, Tidefelt U, Uggla B, Yachnin J, Juliusson G, Moshfegh A, Paul C, Wiman KG, Andersson PO. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol. 2012 Oct 10;30(29):3633-9. doi: 10.1200/JCO.2011.40.7783. Epub 2012 Sep 10. PubMed 22965953 ↗
  • Deneberg S, Cherif H, Lazarevic V, Andersson PO, von Euler M, Juliusson G, Lehmann S. An open-label phase I dose-finding study of APR-246 in hematological malignancies. Blood Cancer J. 2016 Jul 15;6(7):e447. doi: 10.1038/bcj.2016.60. No abstract available. PubMed 27421096 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Jul 2019, 23 months.

Results were first posted in Jul 2022, 3 years after primary completion.

Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 23 months is below that.

Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2017
First posted
Aug 31, 2017
StartActual
Jul 31, 2017
Primary completionActual
Jul 10, 2019
CompletionActual
Jul 10, 2019
Results first posted
Jul 21, 2022
Last update
Mar 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03268382
Lead sponsor
Aprea Therapeutics
Responsible party
Sponsor
First posted
Aug 31, 2017
Start date
Jul 31, 2017
Primary completion
Jul 10, 2019
Completion
Jul 10, 2019
Results posted
Jul 21, 2022
Last update
Mar 17, 2025

Study contacts

Charlie Gourley, BSc, MB ChB, PhD, FRCP
principal investigator · Edinburgh Cancer Research Centre, The University of Edinburgh

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eprenetapopt

Start the discussion